湖北宜化(000422.SZ):擬吸收合併全資子公司新宜化工
格隆匯6月13日丨湖北宜化(000422.SZ)公佈,公司於2025年6月13日召開的第十屆董事會第四十九次會議審議通過了《關於吸收合併全資子公司的議案》,爲進一步優化管理架構,提高運營效率,降低管理成本,公司擬吸收合併全資子公司湖北新宜化工有限公司(以下簡稱“新宜化工”)。本次吸收合併完成後,新宜化工的獨立法人資格將被註銷,其全部資產、債權、債務及其他一切權利與義務將由公司依法享有和承擔。同時,前次募集資金投資項目“潔淨煤加壓氣化多聯產技改搬遷升級項目”的主體由新宜化工變更爲公司,該項目的實施地點、實施內容等其他事項不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.